This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Todor, D. R. Articles by Chyatte, D. Search for Related Content PubMed PubMed Citation Articles by Todor, D. R. Articles by Chyatte, D.

(Stroke. 1998;29:1580-1583.)
© 1998 American Heart Association, Inc.

Original Contributions

Identification of a Serum Gelatinase Associated With the Occurrence of Cerebral Aneurysms as Pro-Matrix Metalloproteinase-2

D. Roxanne Todor, MD; Isabel Lewis, BS; Gerry Bruno, MS; Douglas Chyatte, MD

From the Cerebrovascular Research Laboratory, Section of Cerebrovascular Surgery, Department of Neurosurgery, The Cleveland Clinic Foundation (Ohio).

Correspondence to Douglas Chyatte, MD, Section of Cerebrovascular Surgery, Department of Neurosurgery–S80, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195. E-mail chyattd{at}cesmtp.ccf.org

Background and Purpose—Subarachnoid hemorrhage from intracranial aneurysm rupture produces a severe form of stroke. Extracellular matrix remodeling is associated with cerebral aneurysms and may play a role in the formation or rupture of these lesions. We previously reported a 3-fold increase in a 72-kDa serum gelatinase in a subgroup of aneurysm patients. The purpose of the present study was to further characterize and identify this gelatinase.

Methods—Serum samples were collected from surgical patients with intracranial aneurysms. The following series of experiments was designed to further characterize and identify the predominant serum gelatinase found in the subgroup of patients with increased gelatinase activity. Gelatin zymography was performed on native serum samples and compared with serum that had been pretreated with a known metalloproteinase activator (4-aminophenylmercuric acetate [APMA]). Gelatin zymography was repeated in the presence of a matrix metalloproteinase (MMP) inhibitor (EDTA) and a serine proteinase inhibitor (phenylmethylsulfonyl fluoride [PMSF]). Final identification was made by Western blotting with the use of monoclonal antibodies to MMP-2 and MMP-9.

Results—A consistent gelatinolytic band (72 kDa) was identified in all serum samples (n=60). Pretreatment of the serum by APMA (n=60) lowered the molecular weight of the band to 66 kDa. The band was inhibited by EDTA (n=10) but not PMSF (n=10), thus characterizing the circulating 72-kDa gelatinase as an inactive pro-MMP. Western blotting (n=20) identified the 72-kDa band as MMP-2.

Conclusions—These findings confirm that the increased gelatinolytic activity observed in vitro in a subset of cerebral aneurysm patients is due to pro-MMP-2.

Key Words: cerebral aneurysm • gelatinases • metalloproteinases

This article has been cited by other articles:

				T. Aoki, H. Kataoka, T. Moriwaki, K. Nozaki, and N. Hashimoto Role of TIMP-1 and TIMP-2 in the Progression of Cerebral Aneurysms Stroke, August 1, 2007; 38(8): 2337 - 2345. [Abstract] [Full Text] [PDF]

				W.I. Mangrum, F. Farassati, R. Kadirvel, C.P. Kolbert, S. Raghavakaimal, D. Dai, Y.H. Ding, D. Grill, V.G. Khurana, and D.F. Kallmes mRNA Expression in Rabbit Experimental Aneurysms: A Study Using Gene Chip Microarrays AJNR Am. J. Neuroradiol., May 1, 2007; 28(5): 864 - 869. [Abstract] [Full Text] [PDF]

				Y. Mineharu, K. Inoue, S. Inoue, S. Yamada, K. Nozaki, N. Hashimoto, and A. Koizumi Model-Based Linkage Analyses Confirm Chromosome 19q13.3 as a Susceptibility Locus for Intracranial Aneurysm Stroke, April 1, 2007; 38(4): 1174 - 1178. [Abstract] [Full Text] [PDF]

				T. Aoki, H. Kataoka, M. Morimoto, K. Nozaki, and N. Hashimoto Macrophage-Derived Matrix Metalloproteinase-2 and -9 Promote the Progression of Cerebral Aneurysms in Rats Stroke, January 1, 2007; 38(1): 162 - 169. [Abstract] [Full Text] [PDF]

				C. Z. Lee, B. Xu, T. Hashimoto, C. E. McCulloch, G.-Y. Yang, and W. L. Young Doxycycline Suppresses Cerebral Matrix Metalloproteinase-9 and Angiogenesis Induced by Focal Hyperstimulation of Vascular Endothelial Growth Factor in a Mouse Model Stroke, July 1, 2004; 35(7): 1715 - 1719. [Abstract] [Full Text] [PDF]

				D. Krex, H. Rohl, I. R. Konig, A. Ziegler, H. K. Schackert, and G. Schackert Tissue Inhibitor of Metalloproteinases-1, -2, and -3 Polymorphisms in a White Population With Intracranial Aneurysms Stroke, December 1, 2003; 34(12): 2817 - 2821. [Abstract] [Full Text] [PDF]

				N. Lods, P. Ferrari, F. J. Frey, A. Kappeler, C. Berthier, B. Vogt, and H.-P. Marti Angiotensin-Converting Enzyme Inhibition but not Angiotensin II Receptor Blockade Regulates Matrix Metalloproteinase Activity in Patients with Glomerulonephritis J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2861 - 2872. [Abstract] [Full Text] [PDF]

				T. Hashimoto, G. Wen, M. T. Lawton, N. J. Boudreau, A. W. Bollen, G.-Y. Yang, N. M. Barbaro, R. T. Higashida, C. F. Dowd, V. V. Halbach, et al. Abnormal Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Brain Arteriovenous Malformations * Growth and Bleeding in BAVM: Another Role for MMPs Stroke, April 1, 2003; 34(4): 925 - 931. [Abstract] [Full Text] [PDF]

				A. T. Askari, M.-L. Brennan, X. Zhou, J. Drinko, A. Morehead, J. D. Thomas, E. J. Topol, S. L. Hazen, and M. S. Penn Myeloperoxidase and Plasminogen Activator Inhibitor 1 Play a Central Role in Ventricular Remodeling after Myocardial Infarction J. Exp. Med., March 3, 2003; 197(5): 615 - 624. [Abstract] [Full Text] [PDF]

				I. Loftus and M. Thompson The role of matrix metalloproteinases in vascular disease Vascular Medicine, May 1, 2002; 7(2): 117 - 133. [Abstract] [PDF]